Geoffrey Dusheiko - Selected Publications#

Google scholar H Index 82 Citations 33367 i10-index 251 103

1. Dusheiko, G., Kew, M. C., Joffe, B. I., Lewin, J. R., Mantagos, S., & Tanaka, K. (1979). Recurrent hypoglycemia associated with glutaric aciduria type II in an adult.. N Engl J Med, 301(26), 1405-1409. doi:10.1056/NEJM197912273012601

I and colleagues reported the onset of a severe life-threatening organic aciduria in adult. The paper served to indicate the advantage of careful bedside observation coupled with state of the art biochemical confirmation of the findings (Dr Kay Tanaka, Yale University) I was a registrar at the time. The article merited an editorial in the New England Journal of Medicine.

2.Dusheiko, G., Dibisceglie, A., Bowyer, S., Sachs, E., Ritchie, M., Schoub, B., & Kew, M. (1985). Recombinant leukocyte interferon treatment of chronic hepatitis B.. Hepatology, 5(4), 556-560. doi:10.1002/hep.1840050406

We investigated the efficacy of a relatively prolonged course of recombinant leukocyte interferon treatment in 14 chronic HBsAg‐, HBeAg‐, hepatitis B virus DNA‐ and DNA polymerase‐positive carriers. The efficacy of recombinant leukocyte interferon therapy is restricted, but it may be of benefit in a proportion of carriers, if these carriers can be precisely identified. Many subsequent studies performed worldwide confirmed these findings.

3. Grellier, L., Mutimer, D., Ahmed, M., Brown, D., Burroughs, A. K., Rolles, K., Dusheiko, G. (1996). Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.. Lancet, 348(9036), 1212-1215. doi:10.1016/s0140-6736(96)04444-3 We collaborated with the transplant unit at the University of Birmingham and were the first to show that Lamivudine treatment would prove useful in preventing recurrence of hepatitis B after liver transplantation. Nucleoside analogue is now offered before liver transplantation to patients positive for HBsAg and has profoundly reduced the risk of recurrent hepatitis B in the grafted liver.

4. Webster, G. J. M., Hallett, R., Whalley, S. A., Meltzer, M., Balogun, K., Brown, D., . . . Dusheiko, G. M. (2000). Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. The Lancet, 356(9227), 379-384. doi:10.1016/S0140-6736(00)02529-0 We, together with colleagues at Public Health England investigated an outbreak of hepatitis B in patients who had attended and autohaemotherapy clinic between January, 1997, and February, 1998. HBV DNA was sequenced to assess the relatedness of the virus identified in the cases. Serum samples were received from 352 patients and four staff members.

5. Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., . . . ADVANCE Study Team. (2011). Telaprevir for previously untreated chronic hepatitis C virus infection.. N Engl J Med, 364(25), 2405-2416. doi:10.1056/NEJMoa1012912 A multicentre controlled clinical trial published in the New England Journal of Medicine. Telaprevir with peginterferon–ribavirin, as compared with peginterferon–ribavirin alone, was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.

6. Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., . . . VALENCE Investigators. (2014). Sofosbuvir and ribavirin in HCV genotypes 2 and 3.. N Engl J Med, 370(21), 1993-2001. doi:10.1056/NEJMoa1316145

We conducted a study involving patients with HCV genotype 2 or 3 infection, some of whom had undergone previous treatment with an interferon-based regimen. These data indicated the need for development of further antiviral therapies to optimize treatment for gentotype 3.

7.Pawlotsky, J. -M., Aghemo, A., Back, D., Dusheiko, G., Forns, X., Puoti, M., & Sarrazin, C. (2015). EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology, 63(1), 199-236. R

With three new HCV DAAs approved, IFN-free combinations were broadly used across Europe in 2014, initially as part of early access programs, essentially in patients with advanced liver disease (fibrosis METAVIR score F3 or F4).

8.Dusheiko, G. (2018). A Shift in Thinking to Reduce Mother-to-Infant Transmission of Hepatitis B. N Engl J Med, 378(10), 952-953. doi:10.1056/NEJMe1801662

This invited editorial focused on the increasing disease burden from hepatitis B virus infection and the ongoing risk of transmission to infants and therefore chronic disease from perinatal HBV infection.

WHO guidelines published in August 2020 have now promulgated antiviral prophylaxis in pregnancy.

9.Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019). Hepatitis C. Lancet, 394(10207), 1451-1466. doi:10.1016/S01 An up to date review of hepatitis C

10. Carey, I., Gersch, J., Wang, B., Moigboi, C., Kuhns, M., Cloherty, G., . . . Agarwal, K. (2020). Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology 72(1), 42-57. doi:10.1002/hep.31026

We showed in this paper that HBcrAg and pregenomic RNA are sensitive markers of continued transcription cccDNA in E antigen -negative patients despite suppression by nucleoside analogues. The presence of these markers indicated severe relapse when nucleoside analogue therapy was stopped.